CLINICAL_TRIALS
trial_result
· 2017-07-11
Clinical Trial Update: A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia [Phase 3]
Summary
Phase 3 trial results for NBI-98854 in tardive dyskinesia have been posted following completion of the study.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 3 | Status: COMPLETED | Results posted: 2017-07-11